METheraHld (METX.CN)
- Previous Close
9.50 - Open
9.87 - Bid 9.00 x --
- Ask 9.87 x --
- Day's Range
9.87 - 9.87 - 52 Week Range
0.75 - 11.00 - Volume
100 - Avg. Volume
122 - Market Cap (intraday)
258.49M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.05 - Earnings Date Apr 11, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. Its lead candidate, h1B11-12, is a glycoprotein cytokine antibody drug that targets a key protein involved in the generation of suppressive myeloid cells for the treatment of colorectal cancer. The company also develops D094 and D099, which are small molecule myeloid targeted prodrug candidates to treat cancer; and myeloid targeting lipid nanoparticles (LNPS) formulations. ME Therapeutics Holdings Inc. was founded in 2014 and is headquartered in Vancouver, Canada.
www.metherapeutics.comRecent News: METX.CN
View MorePerformance Overview: METX.CN
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: METX.CN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: METX.CN
View MoreValuation Measures
Market Cap
258.49M
Enterprise Value
256.59M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
117.77
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-46.43%
Return on Equity (ttm)
-73.59%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-1.31M
Diluted EPS (ttm)
-0.05
Balance Sheet and Cash Flow
Total Cash (mrq)
2M
Total Debt/Equity (mrq)
4.47%
Levered Free Cash Flow (ttm)
--